AI Proteins has closed a $41.5 million Series A financing to accelerate the development of de novo #miniproteins! The round was led by Mission BioCapital and SANTÉ, with robust participation from existing investors.

See the official press release for details:
www.businesswire.com/news/home/20...

Discovery of d-Miniprotein Inhibitors of PD-1/PD-L1 Interaction via Mirror-Image Phage Display against Synthetic d-PD-1 As a member of the immune checkpoint, PD-1 is acknowledged as a key player in immune regulation and a hot target for cancer immunotherapy. The broad and flat binding interface of PD-1 to PD-L1 poses a...

Great talk by Xuechen Li at #ISCPDD. He talked about the use of #miniproteins in #DrugDiscovery. Exciting insights into the synthesis of large libraries and their screening by #PhageDisplay including the use of mirror image phage display.
pubs.acs.org/doi/10.1021/...
#ChemSky #ChemBio #Peptides

This is the foundation for our next chapter at @aiproteins.com. We’ve industrialized the process of creating #miniproteins de novo while fully controlling every aspect of their activity and properties.

In this talk, I explain how our #miniproteins can interact with as many targets as needed to deliver the exact therapeutic outcome that patients require. This level of sophistication is unprecedented and will impact indications across oncology, inflammation, and beyond.

#IPISeminar alert 🔔 Friday at 2 p.m. ET, Chris Bahl of AI Proteins will share the challenges of incorporating #artificialintelligence into #proteindesign & the impact reimagined #miniproteins can have on therapeutics. Join us through the QR code or follow the Zoom link on our calendar! rb.gy/xcee9l

It was an honor to speak from the main stage at TED last week about our work at AI Proteins

Our mission is to design the next generation of therapeutics built from de novo #miniproteins, and this was an unbelievable opportunity to help shape the broader conversation about the future of biologics

Institute for Protein Innovation Receives Grant from Chan Zuckerberg Initiative to Develop Next-Generation Protein Tools for Neuroscience Research Funding supports creation and open distribution of critical research tools to accelerate neuroscience discoveries Boston, Massachusetts, February 12, 2025

Breaking: IPI receives $500K @chanzuckerberg.bsky.social grant to make next-gen #proteintools for #neuroscience, including #glialcell research tools w/ Philip De Jager @columbiamed.bsky.social & AI-designed #miniproteins w/ Debora Marks @harvardmed.bsky.social
https://buff.ly/3CLooBU

Mireia Solà Colom, Head of Immunotherapeutics at AI Proteins, presents our latest progress on the design and optimization of immune cell engagers built from our de novo #miniproteins

Mireia Solà Colom gave an incredible seminar at @bpdmc.bsky.social last week, and I'm very excited for her to share some details about what we've built at @aiproteins.bsky.social and how well our #miniproteins perform as therapeutics

Our mission is to make as many new drugs as possible, and to get them to the patients who desperately need them as fast as we can. This is why I am so excited to share the news that we are working with @bms-news.bsky.social to create novel medicines using our #miniproteins.

My group and I left academia together to found @aiproteins.bsky.social, and we did so because of our shared belief in the potential for #miniproteins to improve people's lives.

I started working on designing #miniproteins de novo in 2012 when I joined David Baker's lab for my postdoc at the newly formed @uwproteindesign.bsky.social. Back then, it had never been done before.